Live vs. Killed Vaccines

Live_vs_killed_vaccines.png
Note: In addition to immuncompromised patients (in most cases), pregnant women should not receive live vaccines because of a theoretic risk of transmitting the live agent to the fetus


Immune Deficiency Foundation Medical Advisory Committee (2014)

IDFMAC vaccine recs.png



CDC Vaccination of Immunocompromised (Primary and Secondary) Persons






CDC Contraindications for MMR/Varicella for Patients on Biologics


Abatacept
Orencia
CTLA-4
Adalimumab
Humira
TNF blocker
Alefacept
Amevive
CD2
Alemtuzumab
Campath
Anti-CD52
Anakinra
Kineret
IL-1
Basiliximab
Simulect
IL-2R/CD25
Bevacizumab
Avastin
VEGF
Certolizumab pegol
Cimzia
TNF blocker
Cetuximab
Erbitux
EGFR
Daclizumab
Zenapax
IL-2R
Etanercept
Enbrel
TNF blocker
Glatiramer acetate
Copaxone
Immunomodulatory; target unknown
Golimumab
Simponi
TNF blocker
Ibritumomab tiuxetan
Zevalin
CD20 with radioisotope
Imatinib mesylate
Gleevec, STI 571
Signal transduction inhibitor/
protein-tyrosine kinase inhibitor
Infliximab
Remicade
TNF blocker
Interferon alfa
Pegasys, PegIntron
Block hepatitis C viral replication
Interferon beta-1a
Avonex, Rebif
Immunomodulatory; target unknown
Interferon beta-1b
Betaseron
Immunomodulatory; target unknown
Natalizumab
Tsabri
α4-integrin
Panitumumab
Vectibix
EGFR
Rilonacept
Arcalyst
IL-1
Rituximab
Rituxan
CD20
Sunitinib malate
Sutent
Multikinase inhibitor
Tocilizumab
Actemra
IL-6
Tositumomab
Bexxar
CD20 with radioisotope
Trastuzumab
Herceptin
Human EGFR 2 (HER2)
Ustekinumab
Stelara
IL-12, IL-23



References